Curanex Pharmaceuticals (CURX) EBIT (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly EBIT came in at -$3.1 million in Q4 2025, down 1998.61% YoY from $162889.6 in Q4 2024, and down 225.09% on a QoQ basis from -$951327.0 in Q3 2025.
Curanex Pharmaceuticals (CURX) EBIT (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of EBIT data on file, last reported at -$3.1 million in Q4 2025.
- Quarterly EBIT fell 1998.61% year-over-year to -$3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.2 million (changed N/A YoY) and the FY2025 annual result came in at -$4.2 million, down 1061.19% from the prior year.
- EBIT fell to -$3.1 million in Q4 2025, from -$951327.0 in the prior quarter.
- In the past five years, EBIT ranged from a high of -$57658.0 in Q2 2025 to a low of -$3.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Curanex Pharmaceuticals | 6.11 Mn | 1.11 Mn | - | -3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.09 Mn |
| Sep 30, 2025 | -951,327.00 |
| Jun 30, 2025 | -57,658.00 |
| Dec 31, 2024 | -147,366.00 |
| Sep 30, 2024 | -93,295.00 |